Business Wire

ADVA

5.5.2020 09:02:06 CEST | Business Wire | Press release

Share
FUNET trials ADVA FSP 3000 TeraFlex™ to dramatically expand network capacity

ADVA (FSE: ADV) today announced that CSC – IT Center for Science, which operates the Finnish University and Research Network (FUNET), has transported 400Gbit/s over its existing long-haul network using the ADVA FSP 3000 TeraFlex™ . The trials pave the way for ultra-fast access to Finland’s supercomputers and could offer a major boost to Europe’s research and education community. They also demonstrated the terminal’s ability to carry 1200Gbit/s channels for the transport of 3x 400GbE over a live meshed ROADM infrastructure. What’s more, the trials highlighted how TeraFlex™ maximizes spectral efficiency in any open line system. Using the terminal’s ultra-flexible modulation and adaptive baud rate capabilities, FUNET also achieved new levels of bandwidth efficiency – and therefore could significantly reduce opex – for 400GbE, 100GbE and lower-speed services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200505005036/en/

“These trials demonstrate how the ADVA FSP 3000 TeraFlex™ performs over long-haul distances, and the results were well above our expectations. It was the first time when we really needed a gridless line system to enable a full choice of line speeds and modulations. The powerful performance of TeraFlex™ and its flexibility to tune line speed and modulation, will allow us to optimize spectrum usage and minimize the cost of providing services to our users,” said Jani Myyry, FUNET network, CSC – IT Center for Science. “Our network provides essential connectivity for research and education institutes in Finland and throughout the Nordics. Initially we were aiming for transport based on 100Gbit/s and 200Gbit/s but are now seeing an increasing need for speeds above that, up to use cases requiring a bandwidth of multiple Tbit/s. TeraFlex and our ADVA open line system infrastructure enable us to efficiently scale our network with line speeds of 400Gbit/s and above. The trials show how TeraFlex™ dramatically increases flexibility and efficiency for 100GbE and 400GbE transport over long-haul distances.”

FUNET’s tests underline the ability of the ADVA FSP 3000 TeraFlex™ to massively increase the capacity of existing terrestrial long-haul networks. The low-power 1RU terminal enables channels of up to 1200Gbit/s for 3x 400GbE services and a total capacity of 3.6Tbit/s. Using network telemetry, software-defined fractional QAM modulation and adaptive baud rate capabilities, the solution is able to ensure maximum spectral efficiency at every point in the network. This enables operators to leverage previously unused optical spectrum so that deployed infrastructure can be made to transport far more data. As well as succeeding with 600Gbit/s transport over 278km and with 400Gbit/s over 2,844km, the trials showed the power of harnessing granular increments with speeds of 300Gbit/s over 4,681km.

“These tests show how it’s now possible to optimize all optical paths over any reach. They demonstrate to the research and education industry that there’s a new way for long-distance networks to support soaring data demand. With its ultra-flexible modulation, our compact and open FSP 3000 TeraFlex™ is the key to unlocking maximum value in any network,” commented Henning Hinderthür, VP, product line management, ADVA. “Together with the CSC – IT Center for Science, we’ve shown how deployed infrastructure operating with coherent channels can transport traffic at unprecedented speeds. And not only that. Our unique TeraFlex™ solution also enhances performance, improves port efficiency and delivers major opex savings. It massively increases the efficiency of existing 100GbE connectivity, while also providing a way to meet the needs of emerging data-hungry applications for 400GbE and beyond.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com .

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye